Diversion- and/or abuse-resistant compositions and methods for making the same
View Patent ↗A composition formulated for diversion- and/or abuse-resistance, includes at least one active pharmaceutical ingredient (API), each present in an acidic form, a first compound capable of coupling to the acidic form of the API to form a complex, where the resulting complex is resistant to separation by conventional separation methods, and a second compound capable of preferentially coupling to the first compound to thereby release the API from the complex.
1. A composition comprising:
(a) at least one acid salt of an opioid active pharmaceutical ingredient (API);
(b) a first compound coupled to the acid salt of the opioid API to form a water-insoluble complex, and enabling the first compound to undergo oxidization under basic conditions, to form a fine particulate precipitate; and
(c) a second compound in an amount sufficient for coupling to the first compound in an aqueous environment, whereby the acid salt of the opioid API is released from the complex.
2. The composition of claim 1 wherein the first compound is astringent.
3. The composition of claim 1 wherein the an acid salt of an opioid API is a hydrochloric acid salt.
4. The composition of claim 3 wherein the opioid is natural, synthetic, semi-synthetic or combinations thereof.
5. A composition comprising:
an acid salt of an opioid active pharmaceutical ingredient
at least one polyphenol, said acid salt and said polyphenol forming a water-insoluble complex; and
at least one water soluble polymer.
6. The composition of claim 5 wherein the polyphenol is selected from the group consisting of hydrolysable tannins, phenylpropanoids, compounds having at least one phenolic subcomponent selected from the group consisting of phenols, pyrocatechols, pyrogallols, resorcinol, phloroglucinol, and hydroquinone, and combinations thereof.
7. The composition of claim 5 wherein the polyphenol is selected from the group consisting of tannins, tannic acid, gallic acid, and combinations thereof.
8. The composition of claim 5 wherein the water soluble polymer is selected from the group consisting of polyalkyleneoxides, polyvinyl pyrrolidone, and combinations thereof.
9. The composition of claim 8 wherein the polyalkyleneoxides are selected from the group consisting of polyethylene glycol, polypropylene glycol, and combinations thereof.
10. The composition of claim 9 wherein the polyethylene glycol has a molecular weight of from about 400 Da to 400,000 Da.
11. The composition of claim 5 wherein the polyphenol is astringent.
12. The composition of claim 5 wherein the polyphenol is natural, synthetic, semi-synthetic or combinations thereof.
13. The composition of claim 5 , wherein the acid salt of an opioid active pharmaceutical ingredient comprises oxycodone hydrochloride, the polyphenol comprises tannic acid, the water soluble polymer comprises polyethylene glycol, and the oxycodone hydrochloride, polyphenol and water soluble polymer are present in a weight ratio of about 1:1:7.
14. The composition of claim 1 wherein the sum of the amounts of the first compound and the second compound exceed the amount of the acid salt of the API.
15. The composition of claim 1 wherein the weight ratio of the (a):(b):(c) is in the range of from about 1:1-10:1-30.
16. The composition of claim 15 wherein the weight ratio is from about 1:1-3:5-10.
17. The composition of claim 16 wherein the weight ratio is about 1:1:7.
18. The composition of claim 1 wherein the opioid is selected from the group consisting of opiates and combinations thereof.
19. The composition of claim 1 wherein the acid salt of an opioid API comprises a compound selected from the group consisting of: oxycodone hydrochloride, morphine hydrochloride, hydrocodone hydrochloride, oxymorphone hydrochloride, and combinations thereof.
20. The composition of claim 1 where in active pharmaceutical ingredient comprises oxycodone hydrochloride, the first compound comprises tannic acid and the second compound comprises polyethylene glycol.
21. The composition of claim 20 further comprising a surfactant.
22. The composition of claim 21 in the form of a capsule.
23. The composition of claim 1 wherein the weight ratio of the (a)•(b)•(c) is in the range of about 1:0.5-10:0.5-30.
24. A pharmaceutical composition for administration to a warm-blooded animal for release of an opioid active pharmaceutical active (API) for a therapeutic purpose, comprising:
(a) a therapeutically effective amount of at least one acid salt of an opioid API;
(b) a first compound coupled to the acid salt of the opioid API to form a water-insoluble complex enabling the first compound to undergo oxidization under basic conditions, to form a fine particulate precipitate;
(c) a second compound in an amount sufficient for preferentially coupling to the first compound in an aqueous environment, whereby the acid salt of the API is released from the complex; and
(d) a pharmaceutically acceptable carrier.
25. The pharmaceutical composition of claim 24 wherein the first compound is astringent.
26. The pharmaceutical composition of claim 24 wherein the API is selected from the group consisting of: oxycodone hydrochloride, morphine hydrochloride, hydrocodone hydrochloride, oxymorphone hydrochloride, and combinations thereof.
27. The pharmaceutical composition of claim 24 wherein the first compound is at least one polyphenol.
28. The pharmaceutical composition of claim 24 wherein the second compound is at least one water soluble polymer.
29. The pharmaceutical composition of claim 24 further comprising at least one additive selected from the group consisting of surfactants, gel forming compounds, and combinations thereof.
30. The pharmaceutical composition of claim 24 in the form of tablets, soft capsules, hard capsules, gels, and liquid formulations.
31. A pharmaceutical composition for administration to a warm-blooded animal for release of an opioid active pharmaceutical ingredient (API) for a therapeutic purpose comprising:
a first complex comprising an opioid acid salt of an API bound to a polyphenol, said polyphenol being capable of undergoing oxidation under basic conditions to form a fine particulate precipitate;
a water soluble polymer in an amount sufficient for preferentially binding to the polyphenol in an aqueous environment, whereby the acid salt of the API of the first complex is released from said first complex.
32. The pharmaceutical composition of claim 31 wherein the polyphenol is astringent.
33. The pharmaceutical composition of claim 31 wherein the API is selected from the group consisting of: oxycodone hydrochloride, morphine hydrochloride, hydrocodone hydrochloride, oxymorphone hydrochloride, and combinations thereof.
34. The pharmaceutical composition of claim 31 wherein the water soluble polymer preferentially binds to the polyphenol in an acidic or slightly basic environment.